TRANSCODE THERAPEUTICS, INC.
  • Home
  • About
    • Who We Are
    • Leadership
    • Partnering
  • Focus
  • Science
  • Pipeline
    • Platform
    • TTX-MC138
    • Other Candidates
  • Resources
  • Investors
  • Careers

Platform

Our Platform

TransCode Therapeutics has created seven distinct product families of RNA drug/diagnostic candidates with the objective of improving cancer patient outcomes. Our lead therapeutic candidate,  TTX-MC138, currently our primary focus, is targeting metastatic cancer, which has been shown to be responsible for the majority of all cancer deaths annually.
Picture
More on TTX-MC138
​Currently we are continuing research on a variety of both diagnostic and therapeutic approaches targeting biomarkers broadly prevalent across numerous tumor types. ​

Advancing a Pipeline of First-in-Class RNA Therapeutic Candidates

Picture
Additionally, TransCode’s other drug candidates, TTX-siPDL1, 64Cu-TTX-MC138, TTX-siLIN28b, TTX-RIGA, TTX-CRISPR and TTX-mRNA, focus on treating cancer using RNA technology made possible through our proprietary delivery platform.
other candidates
Learn more about how TransCode is  advancing new RNA therapies through a modular design engine.
Picture
Download
Preview
Picture
TTX is an investigational platform encompassing therapeutic candidates (including TTX-MC138) and diagnostics which remain in development. Their safety and efficacy have not yet been evaluated by the FDA or any other regulatory agency.

Home

About

About
leadership

Partnering
​Careers     

Focus

Focus

Science

Science
​Resources

Pipeline

PIPELINE
TTX-MC138
​OTHER CANDIDATES

Contact/Support

Contact
​TERMS OF USE
PRIVACY POLICY
FCOI Policy
​
© TRANSCODE THERAPEUTICS, INC. 2022.​ ALL RIGHTS RESERVED.
  • Home
  • About
    • Who We Are
    • Leadership
    • Partnering
  • Focus
  • Science
  • Pipeline
    • Platform
    • TTX-MC138
    • Other Candidates
  • Resources
  • Investors
  • Careers